Vexing problems oftimes lead to creative solutions. OpGen's robust ingenuity is a case in point.
Problem: "Antibiotic resistance is a global threat. There is no system in place to track antibiotic resistance globally. Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats." -U.S. Center for Disease Control
Enter OpGen, Inc. Press Releases
OpGen, Inc. (Gaithersburg, MD, USA) (Nasdaq OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to guide clinicians with rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDRO). Subsidiaries include Curetis GmbH and
Ares Genetics GmbH*. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI. Learn more
OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, PNA FISH, Quick Fish, Acuitas® Lighthouse, and the ARES Technology Platform. The Ares Technology Platform includes ARESdb (db=database) that uses NGS (next generation sequencing) technology and AI-powered bioinformatics solutions to predict antibiotic response (resistance). Artificial intelligence based DNA testing revolutionizes infectious disease diagnostics and therapeutics.* Patient outcomes improved; costs reduced. Learn more
"Time is of the essence in cases of severe infections, not infrequently a question of life or death, and knowing what not to prescribe is as important as knowing what to prescribe."
OpGen Corporate Overview 06-Oct-2020 (Recommended viewing)
*02Oct2020 OpGen's wholly owned Ares Genetics GmbH* (Vienna) won the Austria State Prize for innovation with their Project "ARESupa- Molecular Antibiotic Resistance Diagnostics using Artificial Intelligence - With a (Ares Genetics) universal pathogen test, antibiotic resistance from germs can be predicted quickly and accurately."
OpGen subsidiary Ares Genetics, which combines Next Generation Sequencing (NGS) with ARESdb, is the world‘s most comprehensive database on the genetics of antibiotic resistance. ARESdb is also the world’s largest database of genetic antibiotic resistance markers and predictive AMR panels. ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally. ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with ~98% accuracy. ARESdb covers 30 years of emerging antibiotic resistance to accurately detect AMR and combines deep whole-genome sequencing data with antibiotic resistance profiles continuously expanded. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI.
UNYVERO IS FDA APPROVED
Unyvero A50 Applications for Major Infectious Disease
BCU — Blood Culture
Analyzes the DNA of 103 pathogens & resistance genes from a
positive blood culture for fast diagnostics of blood stream infections.
Unyvero A50 System *OpGen Partner Curetis BGI COVID-19 Rapid Test Kits approved by US FDA March 29, 2020 "The kits are being used in 70 countries and regions including Japan, Brunei, Thailand, The United Arab Emirates, Egypt and Peru." *OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections June 03, 2020 *OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours June 09, 2020 *Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America July 13, 2020 *OpGen Co-Markets COVID-19 Antibody Test Kit August 09, 2020 *OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19 August 20, 2020
Unyvero A50 Cartridge
Unyvero A30 RQ in development
*Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing September 16, 2020 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.